Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bifidobacterium longum + Synergy 1
- Development stage
- Unknown
- Lead developer
- University of Dundee
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
This product is a synbiotic combination of the probiotic bacterium Bifidobacterium longum and the prebiotic Synergy 1. Bifidobacterium longum is a beneficial gut microbe known for its anti-inflammatory, immunomodulatory, and gut barrier-supporting effects. Synergy 1 is a proprietary blend of inulin and oligofructose (fructooligosaccharides), which serves as a preferential growth substrate for B. longum, enhancing its colonization and activity in the gastrointestinal tract. The mechanism of action involves modulation of the intestinal microbiota composition, reduction of proinflammatory cytokines (such as tumor necrosis factor alpha and interleukin-1 alpha), downregulation of human beta defensins associated with active inflammation, improvement in epithelial regeneration, and restoration of mucosal immune balance. This combination has been studied primarily for use in patients with active ulcerative colitis (UC), where it demonstrated clinical improvement by reducing inflammation markers and promoting mucosal healing[1][2][4].
- Brand names
- Synergy 1Synergy1Synergy-1
- Other names
- bifidobacterium longum/Synergy 1synbiotic therapy (Bifidobacterium longum/Synergy 1)
02
Targets
IL1A (Interleukin 1 alpha)HBD (Exocyst complex component 6)TNFA (Tumor necrosis factor alpha (soluble))
Beyond the preview
Go deeper on bifidobacterium longum + Synergy 1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bifidobacterium longum + Synergy 1.